Sandoz's Chief Operating Officer Discusses the New Initiative Act4Biosimilars

About This Episode:  What is in the future for biosimilars?  In this episode, Pierre Bourdage, Chief Operating Officer at Sandoz, lays out the promise and potential of biosimilars, and the important role they play in healthcare system sustainability. We also hear about the new initiative Act4Biosimilars which addresses the challenges of biosimilar approvability, accessibility, acceptability and affordability, with the goal of increasing the global adoption of biosimilars by at least 30% in 30+ countries by 2030.   Key Takeaways: How biosimilars can fuel competition, innovation and generate savingsThe lasting impact on access for patientsHow Act4Biosimilars works to support biosimilar adoption and access   About the Speaker:  Pierre Bourdage is the Chief Operating Officer of Sandoz, a division of Novartis, driving high quality off-patent medicine accessibility and affordability for millions of patients. He is a member of the Sandoz Executive Committee. His previous roles at Sandoz include Global Head, Biopharmaceuticals Business Unit and Global Head, Sandoz Biopharmaceuticals Strategy and Portfolio. For more information about innovations in clinical research, click here.